Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | LIPA | P38571 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18743944 | 1.00 | EPHX1 (0.33) | EPHX1LIPATDP1ALOX15 | |
| SCHEMBL26003107 | 0.84 | — | — | |
| SCHEMBL26788084 | 0.84 | — | — | |
| SCHEMBL12560566 | 0.84 | — | — | |
| SCHEMBL9396708 | 0.83 | TDP1 (0.31) | TDP1 | |
| SCHEMBL22817576 | 0.79 | — | — | |
| SCHEMBL15706277 | 0.79 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL661220 | 0.78 | TDP1 (0.42) | TDP1 | |
| SCHEMBL22797 | 0.78 | — | — | |
| SCHEMBL5270433 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230167123-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | GENENTECH, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167123-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | GENENTECH, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| WO-2023078426-A1 | COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 上海优理惠生医药有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230000877-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2023-01-05 | — | — | US | disclosed |
| US-7829589-B2 | Sulfonamide compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829589-B2 | Sulfonamide compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20080261970-A1 | Sufonamides and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | EPHX1 2585/4885LIPA 2717/4885TDP1 1038/4885 |
| US-20230167123-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | JAK2, JAK1, JAK3 | EPHX1 1989/4885LIPA 4371/4885TDP1 1560/4885 |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | EZH1, EZH2, IKZF3 | EPHX1 617/4885LIPA 4045/4885TDP1 2356/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | EPHX1 3742/4885LIPA 1436/4885TDP1 448/4885 |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | EPHX1 2332/4885LIPA 4154/4885TDP1 4710/4885 |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | GHSR, GHRHR, SSTR2 | EPHX1 3138/4885LIPA 1001/4885TDP1 4628/4885 |
| US-20230000877-A1 | COMBINATION THERAPY FOR TREATING CANCER | EZH2, DOT1L, EZH1 | EPHX1 2120/4885LIPA 4262/4885TDP1 1340/4885 |
| US-20080261970-A1 | Sufonamides and Uses Thereof | CYP21A2, LPXN, OAT | EPHX1 325/4885LIPA 448/4885TDP1 2832/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | EPHX1 3742/4885LIPA 1436/4885TDP1 448/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | EPHX1 2395/4885LIPA 4244/4885TDP1 4719/4885 |
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | EPHX1 493/4885LIPA 1819/4885TDP1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.